Anaptys Announces Participation in September Investor Conferences
29 août 2024 09h15 HE
|
AnaptysBio, Inc.
SAN DIEGO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that...
Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering
14 août 2024 05h00 HE
|
AnaptysBio, Inc.
SAN DIEGO, Aug. 14, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced the...
Anaptys Announces Second Quarter 2024 Financial Results and Provides Business Update
05 août 2024 16h15 HE
|
AnaptysBio, Inc.
Top-line data expected in December 2024 after having completed enrollment for Phase 2b trial to treat atopic dermatitis (AD) with ANB032, our BTLA agonistTop-line data accelerated and now anticipated...
Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update
09 mai 2024 16h15 HE
|
AnaptysBio, Inc.
Enrollment ongoing for global Phase 2b trial to treat atopic dermatitis (AD) with ANB032, our BTLA agonist; reiterating top-line data anticipated by year-end 2024Enrollment ongoing for global Phase 2b...
Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)
09 mai 2024 16h10 HE
|
AnaptysBio, Inc.
All eight patients from GEMINI-1 who responded to a single intravenous (IV) imsidolimab dose and were subsequently re-randomized to monthly subcutaneous (SC) maintenance dosing of imsidolimab in...
Anaptys to Receive $50 Million in a Capped Non-Recourse Monetization from Amended Agreement with Sagard in Exchange for Additional Jemperli Royalties
09 mai 2024 16h05 HE
|
AnaptysBio, Inc.
Anaptys to receive $50 million upfront cash payment from Sagard HealthcarePrior agreement amended to now expire once Sagard receives a capped payoff of either $600 million if received by March 31,...
Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
11 mars 2024 16h15 HE
|
AnaptysBio, Inc.
Enrollment ongoing for global Phase 2b trial to treat atopic dermatitis (AD) with ANB032, our BTLA agonist, with top-line data anticipated by year-end 2024Enrollment ongoing for global Phase 2b trial...
Anaptys to Present at TD Cowen’s 44th Annual Health Care Conference and 2024 AAD Annual Meeting
29 févr. 2024 09h15 HE
|
AnaptysBio, Inc.
SAN DIEGO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that...
Anaptys to Present at Guggenheim’s 6th Annual Biotechnology Conference
31 janv. 2024 09h15 HE
|
AnaptysBio, Inc.
SAN DIEGO, Jan. 31, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that...
Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals
27 nov. 2023 16h15 HE
|
AnaptysBio, Inc.
Anaptys licenses exclusive global development and commercialization rights to a potential best-in-class BDCA2 modulator portfolioIND filing to support clinical development of ANB101 in autoimmune and...